Helicobacter pylori 제균율 변화와 일차 제균에 영향을 미치는 임상 인자 = The Trend of Eradication Rate of Helicobacter pylori Infection and Clinical Factors That Affect the Eradication of First-Line Therapy

다국어 초록 (Multilingual Abstract)

Background/Aims: Although triple combination therapy containing a proton pump inhibitor (PPI) and two antibiotics is considered as a standard regimen for the first-line anti-Helicobacter pylori treatment, the recent trend of eradication rates following this therapy has been declined in the last few years. The purpose of this study was to investigate the trend of H. pylori eradication rates over the last 9 years and to evaluate are clinical factors affecting eradication rates. Methods: From January 2001 to June 2009, H. pylori eradication rates in 709 patients with documented H. pylori infection who received triple combination therapy for 7 days were retrospectively evaluated according to years and various clinical factors. H. pylori status was evaluated by 13C urea breath test 4-6 weeks after completion of treatment. Results: The overall H. pylori eradication rate was 77.0%. The annual eradication rates from year 2001 to 2009 were 78.9%, 72.5%, 81.0%, 75.0%, 79.1%, 77.1%, 77.8%, 77.8%, and 75.0% by per-protocol analysis. There was no decreasing tendency of the eradiation rate over 9 years (p=0.974). There was no statistical difference in the eradication rates according to age, sex, smoking, alcohol, NSAIDs, underlying diseases, endoscopic diagnosis, and PPI. However, the eradication rate was lower in patients who took aspirin (OR=0.509, 95% CI=0.292-0.887, p=0.001) and antibiotics within 6 months (OR=0.347, 95% CI=0.183-0.658, p=0.001). Conclusions: The H. pylori eradication rate has not changed at Gwangju-Chonnam province in Korea for recent 9 years. Lower eradication rate in aspirin and antibiotics users warrants further attention. (Korean J Gastroenterol 2010;55:368-375)

참고문헌 (Reference)

1 금보라, "프로톤 펌프 억제제 종류에 따른 Helicobacter pylori 제균 효과 비교-Omeprazole, Rabeprazole, Esomeprazole, Lansoprazole-" 대한소화기학회 46 (46): 433-439, 2005

2 남택만, "소화성 궤양 환자에서 표준 삼제요법에 의한 Helicobacter pylori 제균 성적에 영향을 미치는 임상 인자" 대한소화기내시경학회 36 (36): 200-205, 2008

3 조한진, "대구, 경북 지역 Helicobacter pylori 일차 및 이차 치료의 연도별 제균율 변화 : 최근 9년 성적" 대한내과학회 76 (76): 186-192, 2009

4 송종규, "경기서부 단일기관에서 최근 11년간의 헬리코박터 파일로리 제균율 변화" 대한내과학회 76 (76): 303-310, 2009

5 Sargýn M, "Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori" 9 : 1126-1128, 2003

6 Perri F, "Treatment of Helicobacter pylori infection" 8 (8): S53-S60, 2003

7 Huang JQ, "Treatment after failure: the problem of “non-responders”" 45 : 140-144, 1999

8 Erah PO, "The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection" 39 : 5-12, 1997

9 Peterson WL, "The role of antisecretory drugs in the treatment of Helicobacter pylori infection" 11 (11): S21-S25, 1997

10 Suzuki T, "Smoking increases the treatment failure for Helicobacter pylori eradication" 119 : 217-224, 2006

11 Tsukada K, "Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients" 37 : 1265-1268, 2002

12 Lam SK, "Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection" 13 : 1-12, 1998

13 Baena JM, "Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week" 14 : 291-296, 2002

14 Inaba T, "Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype" 17 : 748-753, 2002

15 Kuepper-Nybelen J, "Patterns of alcohol consumption and Helicobacter pylori infection: results of a population-based study from Germany among 6545 adults" 21 : 57-64, 2005

16 Vergara M, "Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication" 18 : 647-654, 2003

17 최유식, "Helicobacter pylori 일차 삼제 제균요법의 연도별 제균율 분석: 단일 기관의 최근 8년 성적" 대한소화기학회 48 (48): 156-161, 2006

18 나현식, "Helicobacter pylori 일차 및 이차 치료의 제균율 변화와 재감염률" 대한소화기학회 50 (50): 170-175, 2007

19 변영혜, "Helicobacter pylori 감염 환자에서 제균을 예측할 수 있는 임상 인자" 대한소화기학회 48 (48): 172-179, 2006

20 Gencer M, "Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease and its relation to pulmonary function tests" 74 : 170-175, 2007

21 Aydemir S, "Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin" 11 : 842-845, 2005

22 Osawa H, "Helicobacter pylori infection and coronary heart disease in Japanese patients" 95 : 14-19, 2001

23 Mégraud F, "H pylori antibiotic resistance: prevalence, importance, and advances in testing" 53 : 1374-1384, 2004

24 Laheij RJ, "Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis" 13 : 857-864, 1999

25 Hunt RH, "Eradication of Helicobacter pylori infection" 100 (100): S42-S50, 1996

26 Miwa H, "Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole" 45 : 77-82, 2000

27 Kawai T, "Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan" 54 : 649-654, 2007

28 Jung SW, "Efficacy of Helicobacter pylori eradication therapy in chronic liver disease" 41 : 134-140, 2009

29 Park SH, "Effect of high-dose aspirin on Helicobacter pylori eradication" 50 : 626-629, 2005

30 Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report" 56 : 772-781, 2007

31 Malfertheiner P, "Cure of Helicobacter pylori-associated ulcer disease through eradication" 14 : 119-132, 2000

32 Caselli M, "Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis" 44 : 101-104, 1989

33 Kauffman G, "Aspirin-induced gastric mucosal injury: lessons learned from animal models" 96 (96): S606-S614, 1989

34 Wang WH, "Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents" 52 : 490-495, 2003

35 Zhang XP, "Aspirin increases susceptibility of Helicobacter pylori to metronidazole by augmenting endocellular concentrations of antimicrobials" 15 : 919-926, 2009

36 Kim JJ, "Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea" 47 : 459-461, 2001

37 Treiber G, "Age-dependent eradication of Helicobacter pylori with dual therapy" 11 : 711-718, 1997

38 김정목, "2003년 우리나라 환자에서 분리한 Helicobacter pylori 균주의 항생제 내성률" 대한소화기학회 44 (44): 126-135, 2004